

Tackling AMR is key to securing previous gains in the fight against TB, Malaria and HIV – Unitaid contributes to these efforts with a focus on LMICs



TUBERCULOSIS

Challenge: 500 000 new cases of MDR-TB world-wide each year, leading to 200 000 deaths.

TB Xpert grant (\$26m):

Improved affordability and access to an innovative test to *diagnose* drug-resistant forms of TB.

EndTB grant (\$60m):

Accelerating *access* to new MDR-TB medicines.

HIV

Challenge: 15% of people starting and 40% of people restarting treatment have been reported to show signs of resistance.

Emerging ARV clinical trials grant (\$70m):


Better understand the potential role of drug candidates less prone to resistance.

New viral load technologies grant (\$147m):

Support scale-up of HIV treatment monitoring to facilitate treatment optimization.

Optimal ART for children grant (\$17m):

Improve coverage and adherence to reduce child mortality.



MALARIA

Challenge: Resistant strain identified in some countries with risk of spreading globally.

Malaria diagnostics grant (\$34m):

Catalyzing access to rapid *diagnostic* tests in the private sector.

IVCC grant (\$65m): Accelerating market update of new tools to manage *insecticide resistance*.

Tackling AMR through Unitaid's core business:
> 50% of Unitaid's portfolio is linked to resistance



SUPPORT THROUGH TECHNICAL REPORTS:

- Technology and market landscapes
- Disease narratives

<https://unitaid.eu/publications/#en>



ENGAGED IN THE GLOBAL RESPONSE:

- Interagency Coordination Group (IACG) on AMR - member
- In the G20 Berlin declaration of health ministers